Inflammation and immune system activation seem to play an important role in the development and progression of dementia. Also concentrations of immune activation marker neopterin are increased in serum and cerebrospinal fluid of some patients with dementia, and a significant relationship is found between concentrations of neopterin and homocysteine. Β vitamin supplementation is able to rapidly slow-down homocysteine formation in patients. However, no change of neopterin was found within one month of such therapy. In this study, scrum concentrations of neopterin and homocysteine were investigated in 58 patients with Alzheimer's disease (n=30), vascular dementia (n=12) and mild cognitive impairment (n=16) during 1 -3 months of supplementation with Β vitamins (Beneitran compositum®) with monthly increasing dose (1-6 tablets a day). No change of neopterin concentrations was observed In the patients groups throughout the whole study period (all ρ >0.05). As was reported earlier, a rapid decline of homocysteine concentrations was achieved already within the first month of supplementation (p <0.01 ), however, no further change of homocysteine was observed later on despite accelerated dose of vitamin supplements. Β vitamin supplementation did not influence neopterin concentrations, and also the longer period of supplementation had no effect. The question remains, if solely the lowering of homocysteine concentrations by folate supplementation could have any beneficial effcct to modulate the course of dementia when the immunopathogenetic mechanisms are not influenced.
Introduction
Among other mechanisms, immune activation is considered to play a role in the pathogenesis of neurodegenerative disorders (1) . Not only in the cerebrospinal fluid, but also in the blood of patients with Alzheimer's dementia (AD) increased concentrations of immune activation markers like soluble receptors for tumor necrosis factor-α, interleukin-2 and neopterin were reported (2, 3) . Neopterin is released by monocyte-derived macrophages stimulated with Thltype cytokine interferon-γ, in parallel also reactive oxygen species (ROS) are formed (4) (5) (6) . Likewise measurement of neopterin concentrations turned out to be a useful tool to monitor cell-mediated immune response and endogenous oxidative stress (5) (6) (7) . Blood and urine neopterin concentrations reflect the severity of virus infections, malignant diseases and autoimmune syndromes (5, 6) , but also in cardiovascular disease (8, 9) , and neurodegenerative disorders (2, 10) a relationship between the extent of immune activation and disease progression have been described.
Moderate hyperhomocysteinemia has been primarily identified as a risk factor for various vascular diseases like atherosclerosis and stroke (11, 12) . But also in patients suffering from neurodegenerative disorders such as Alzheimer's disease (AD) or Parkinson's disease, elevated plasma homocysteine concentrations are common (10, (13) (14) (15) . Homocysteine is a non-protcinogenic sulfur-containing amino acid, which is formed in the methionine cycle. Folate and vitamin Β12 are essential co-factors for the remethylation of homocysteine to methionine, and in a weaker way, vitamin B6 is important for the alternative transsulfuration pathway. In agreement, moderate hyperhomocysteinemia often goes along with deficiencies of folate and vitamin Β12, and supplementation with Β vitamins is able to down-regulate homocysteine concentrations not only in patients, but also in individuals with normal homocysteine and normal vitamin levels (11, 12, 16) .
In patients with dementia, homocysteine concentrations have been shown to be associated with the cognitive status of patients (13, 17, 18) , and it has been claimed that increased homocysteine concentrations may be even involved in pathomechanisms leading to neurodegeneration and dementia. Several mechanisms were proposed regarding the role of accumulated homocysteine in the pathogenesis of diseases, e.g., auto-oxidation of homocysteine e.g. may generate H202 and other radicals, and the resulting oxidative stress would injure surrounding cells. These effects may also be of some relevance for cerebrovascular disorders including dementia ( 1 9-21 ) . However, such theories are mainly based on results of animal experiments or in vitro studies with supra-physiological homocysteine concentrations. The relevance of results for the in vivo situation is uncertain and thus, any causal relationship between moderate hyperhomocysteincmia and the development of diseases is not yet clarified.
In the pathogenesis of most diseases which are associated with hypcrhomocysteinemia, inflammation and immune activation are strongly involved. Accordingly, markers of inflammation and immune activation indicate ongoing immune system activation in patients with atherosclcrotic or neurodegenerative diseases (1, 22, 23) . A correlation between elevated homocysteine concentrations and enhanced production of neopterin was observed in various groups of patients, e.g., in disturbed glucose metabolism (24) , in coronary artery disease (25) and rheumatoid arthritis (26) , and in various neurodegenerative disorders including Parkinson's disease (10) and AD (13, 22, 27) . Also in healthy controls a similar association was reported (28, 29) . Increased neopterin and homocysteine production in parallel were also described in supernatants of stimulated peripheral blood mononuclear cells in vitro (30) . Thus, a causal relationship between inflammation and the development of moderate hyperhomocysteinemia seems plausible (22) , but is not yet unequivocally established.
Earlier we have examined the influence of one month of Β vitamin supplementation on neopterin and homocysteine concentrations in patients with various forms of dementia (31) . A significant drop of homocysteine, but no change of neopterin concentrations was observed. The question arose whether a supplementation period of one month was probably too short to exert any effect on the immune activation status of patients. In this study, the effects of long-term supplementation with Β vitamins are reported. Individuals did not receive vitamin supplementation before baseline measurements. Then they were treated with Beneuran compositum TM ® (Nycomed Austria GmBH, Linz), each tablet containing 50 mg vitamin Bl, 50 mg vitamin B6, 5 mg folic acid and 0.05 mg vitamin Β12, individuals received one single daily dose per day. In the second month dose was increased to one tablet three times a day, and finally in the third month two tablets were given three times a day. Baseline values were taken from 58 persons (AD: 30, VD: 12, MCI: 16), after one month data from 55 patients could be obtained (AD: 29, VD: 1 1, MCI: I 5), after two month data from 36 patients could be obtained (AD: 22, VD: 4, MCI: 10), and after three month data from 29 patients could be obtained (AD: 15, VD: 5, MCI: 9)
Methods

Fifty
Blood samples were collected from fasting individuals, allowed to clot and centrifuged immediately, sera were stored at -30"C until measurement. Total homocysteine concentrations were measured by HPLC as Because not all the data sets showed normal distribution, non-parametric paired Kruskal-Wallis-test was employed throughout for statistical comparisons between different time points. Spearman-rank correlation analysis was performed to assess correlations. Software package SPSS 12.0 for Windows was used for statistical calculations. P-values <0.05 were considered to indicate statistical significance.
Results
Before treatment was started, in all groups a significant percentage of patients presented with homocysteine concentrations >15 pmol/L, the upper limit of normal in persons >60 years, ref. #34), which was also confirmed in our local population of elderly healthy controls (28) : in this study, 69% of patients with AD, 91% with YD and 31 % with MCI had homocysteine levels above this limit (31) . Mean neopterin concentration was highest in patients with VD (mean ± S.F.M.: 14.7 ± 1.7 nmol/L), followed by AD patients (10.9 ± 1.3 nmol/L) and patients with MCI (8.1 ± 2.1 nmol/L). A significant percentage of patients presented with neopterin levels above the upper limit of the normal range, which was defined as 8.7 nmol/L (5). Mean values of folate and vitamin B12 concentrations of all patients groups were above the lower limit of reference ranges (folate: 3 ng/ml, vitamin Β12: 185 pg/ml).
In all groups of patients, an inverse correlation existed between folate and homocysteine concentrations, which was significant in AD and VD, but only a trend in MCI patients (31). Homocysteine and neopterin correlated in patients with VD (r s = 0.544, ρ <0.05) and MCI (r s = 0.711, ρ =0.001), but not in AD (26) . Supplementation with Beneuran compositum ® led to an increase of folate in all groups of patients after one month and also vitamin B12 rose in all groups during treatment (3 1 ). Increasing doses thereafter were reflected by an even higher increase of plasma vitamin levels ( Fig. 1A and B ) After one month of vitamin supplementation, a significant decline of homocysteine was seen in all groups of patients, no further significant decline was observed later on (Fig.  1C) . Neopterin concentrations did not change, neither within one month of vitamin supplementation (31 ) nor in the further course of the study-in none of the investigated groups (Fig. ID) . For results of group comparisons see Table 1 .
during the later follow-up (Fig. ID) . Because increased amounts of neopterin are characteristic for monocyte-derived macrophages and dendritic cells when activated during Thl-type immune response (5, 6), our observation indicates, that Thl-type immune activation status was not influenced by Β vitamin supplementation. Maybe even the longer period of Β vitamin supplementation was not long enough to detect influence on immune activation status, and the size of our study was still small and the drop-out rate of patients during follow-up was rather high. In AD and After initiation of vitamin supplementation, no correlation existed anymore between folate and homocysteine. Also the correlation between homocysteine and neopterin, which was significant at baseline in patients with VD and MCI, did not exist anymore after one month of treatment and later on (all comparisons not significant).
Discussion
Supplementation with B-vitamins led to an increase of folate and vitamin B12 concentrations (Fig. 1A and  B) . This increase was most impressive when the first month of supplementation was compared with baseline levels, it was less marked when the dose was further increased. A significant percentage of our patients with cognitive dysfunction had elevated homocysteine levels at baseline, and an inverse relationship between homocysteine concentrations and folate status existed. Supplementation with Β vitamins was able to decrease homocysteine levels significantly in all investigated groups, and the lowest dose of vitamins already achieved a strong effect, which was not significantly strengthened when dose was increased after one month (Fig. 1C) . Results fit well with literature data, that homocysteine levels can be lowered easily by Β vitamin supplementation (11, 16, 35, 36) .
Neopterin concentrations were not changed by Β vitamin intake. This was true after one month, but also MCI the changes of neopterin concentrations occurred with only little variability, whereas in VD the fluctuation of neopterin levels between different months of follow-up was quite large, however, no significant difference between the various dates of sample collections was observed. (Fig. ID) . Notably, drop-out rate of patients after 1-month of follow-up was highest in the VD group. Still, larger studies are necessary to further address this question. Nevertheless, results agree with findings made in patients with coronary artery disease, in whom Β vitamins did not change concentrations of neopterin and of other inflammatory markers like interleukin-6 and C-reactive protein (37, 38) . All together, data imply that Β vitamin supplementation was insufficient to interfere with immunopathogenetic mechanisms despite correcting hyperhomoycsteinemia.
The relationship between moderate hyperhomocysteinemia and cognitive dysfunction is still unclear. F.levated homocysteine levels may be a marker for inadequate Β vitamin levels and decreased efficiency of vitamin-dependent methylation reactions in brain tissue and thus contribute to cognitive decline (39) . However, data in the literature argue against a beneficial effect of Β vitamin supplementation on the cognitive performance of patients (40) , and so far there is no study which could provide any unequivocal evidence of potential clinical benefit of vitamin supplementation in dementia (41, 42) . The situation compares well to vascular disease, in which treatment with Β vitamins was also unable to improve the future course of the disease (43, 44) .
Neopterin concentrations were elevated in a significant percentage of patients with AD and VD confirming earlier results. Cellular immune system activation is a major trigger for the release of neopterin and ROS by activated macrophages. Concordantly, elevated concentrations of peroxides were found in parallel with elevated neopterin concentrations in the blood of patients with various forms of dementia including VD and AD (45) . Oxidative stress could damage oxidationsensitive substances like vitamin cofactors such as tetrahydrofolate derivatives, the active cofactor forms of folic acid, or vitamin B12 (46) . The endogenous production of ROS during the process of immune activation and the enhanced degradation of folate could underlie the observed relationship between immune activation and hyperhomocysteincmia (22) . In this study, neopterin and homocysteine concentrations correlated at baseline in patients with vascular dementia and mild cognitive impairment, but not thereafter. Obviously increased vitamin levels in the circulation only changed homocysteine but not neopterin production.
Correlations between homocysteine and neopterin concentrations exist in various inflammatory conditions. Decreased availability of Β vitamins, especially of folate seems to be the main trigger for the development of moderate hyperhomocysteinemia. However, especially in Western countries it seems unlikely that insufficient dietary intake of Β vitamins is an appropriate explanation for the high prevalence of moderate hyperhomocysteinemia. In most clinical conditions, folate not only correlated inversely with homocysteine, but also with neopterin concentrations (22, (25) (26) (27) ). An association between homocysteine and the immune activation status also exists in healthy individuals, concentrations of both markers tend to increase with older age, neopterin and homocysteine staying in a close relationship to each other especially in the elderly population (28, 29) . Data indicate a direct link between inflammation and insufficient folate availability: Chronic inflammation and immune system activation could underlie decreased folate availability, even if daily vitamin intake is within the recommended ranges (22) . If this is true, anti-inflammatory treatment to correct underlying immunopathogenetic process could be of more benefit to patients than B-vitamin supplementation alone. In vitro, anti-inflammatory drugs like aspirin (47, 48) and atorvastatin (49, 50) , and also antioxidant compounds like resveratrol (51, 52) were able to concordantly suppress neopterin and homocysteine production in stimulated PBMC. Interestingly, antioxidant vitamin C has been found earlier to improve endothelial function in hyperhomocysteinemic patients (53) . Further studies should be done to investigate whether slowing-down of immune system activation also decreases homocysteine levels.
The immunological background leading to an activated immune system in patients with dementia is unclear. Earlier in patients with AD some relationship between neopterin concentrations and cytomegalovirus (CMV) infection could be established (54) . Such data point to a role of low-grade infections to contribute to immune activation, inflammation and finally development of oxidative stress in patients (Fig. 2) . Importantly, Thl-type cytokine interferon-γ, which is the essential stimulus for neopterin production, is also an important trigger for plaque formation in the patients (55) .
In conclusion, Β vitamins are able to decrease homocysteine concentrations in patients with cognitive dysfunction, whereas levels of immune system activation marker neopterin stay unchanged during vitamin intake. Data suggest that supplementation with folate and vitamin B12 alone may not be enough to influence immunopathogenesis and thus the clinical course of cognitive disorders.
